| Sep 25 |
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump
|
| Sep 25 |
Nvidia, Alibaba, Capricor Therapeutics, TSMC, Tesla: Why These 5 Stocks Are On Investors' Radars Today
|
| Sep 24 |
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
|
| Sep 24 |
Capricor surges on plans to seek FDA approval for lead asset
|
| Sep 24 |
Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
|
| Sep 24 |
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
|
| Sep 23 |
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
|
| Sep 17 |
Capricor Therapeutics, Nippon Shinyaku Sign Binding Term Sheet for Commercialization of Duchenne Muscular Dystrophy Treatment in Europe
|
| Sep 17 |
Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel
|
| Sep 17 |
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
|
